Global Drug of Abuse (DOA) Testing Market Insights, Forecast to 2025

2 Global Drug of Abuse (DOA) Testing Quarterly Market Size Analysis

• 2.1 Drug of Abuse (DOA) Testing Business Impact Assessment - COVID-19
  • 2.1.1 Global Drug of Abuse (DOA) Testing Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Drug of Abuse (DOA) Testing Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Drug of Abuse (DOA) Testing Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Drug of Abuse (DOA) Testing Headquarters and Area Served
• 3.3 Date of Key Players Enter into Drug of Abuse (DOA) Testing Market
• 3.4 Key Players Drug of Abuse (DOA) Testing Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Drug of Abuse (DOA) Testing Segments, By Type

• 4.1 Introduction
  • 1.4.1 Urine
  • 1.4.2 Saliva
  • 1.4.3 Hair
  • 1.4.4 Others
• 4.2 By Type, Global Drug of Abuse (DOA) Testing Market Size, 2019-2021

5 Impact of Covid-19 on Drug of Abuse (DOA) Testing Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospitals
  • 5.5.2 Laboratories
  • 5.5.3 Workplace
  • 5.5.4 At-Home
• 5.2 By Application, Global Drug of Abuse (DOA) Testing Market Size, 2019-2021
  • 5.2.1 By Application, Global Drug of Abuse (DOA) Testing Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Siemens
  • 7.1.1 Siemens Business Overview
  • 7.1.2 Siemens Drug of Abuse (DOA) Testing Quarterly Revenue, 2020
  • 7.1.3 Siemens Drug of Abuse (DOA) Testing Product Introduction
  • 7.1.4 Siemens Response to COVID-19 and Related Developments
• 7.2 Merck
  • 7.2.1 Merck Business Overview
  • 7.2.2 Merck Drug of Abuse (DOA) Testing Quarterly Revenue, 2020
  • 7.2.3 Merck Drug of Abuse (DOA) Testing Product Introduction
  • 7.2.4 Merck Response to COVID-19 and Related Developments
• 7.3 Roche
  • 7.3.1 Roche Business Overview
  • 7.3.2 Roche Drug of Abuse (DOA) Testing Quarterly Revenue, 2020
  • 7.3.3 Roche Drug of Abuse (DOA) Testing Product Introduction
  • 7.3.4 Roche Response to COVID-19 and Related Developments
• 7.4 Thermo Fisher Scientific
  • 7.4.1 Thermo Fisher Scientific Business Overview
  • 7.4.2 Thermo Fisher Scientific Drug of Abuse (DOA) Testing Quarterly Revenue, 2020
  • 7.4.3 Thermo Fisher Scientific Drug of Abuse (DOA) Testing Product Introduction
  • 7.4.4 Thermo Fisher Scientific Response to COVID-19 and Related Developments
• 7.5 Bio-Rad
  • 7.5.1 Bio-Rad Business Overview
  • 7.5.2 Bio-Rad Drug of Abuse (DOA) Testing Quarterly Revenue, 2020
  • 7.5.3 Bio-Rad Drug of Abuse (DOA) Testing Product Introduction
  • 7.5.4 Bio-Rad Response to COVID-19 and Related Developments
• 7.6 Abbott
  • 7.6.1 Abbott Business Overview
  • 7.6.2 Abbott Drug of Abuse (DOA) Testing Quarterly Revenue, 2020
  • 7.6.3 Abbott Drug of Abuse (DOA) Testing Product Introduction
  • 7.6.4 Abbott Response to COVID-19 and Related Developments
• 7.7 Quest Diagnostics
  • 7.7.1 Quest Diagnostics Business Overview
  • 7.7.2 Quest Diagnostics Drug of Abuse (DOA) Testing Quarterly Revenue, 2020
  • 7.7.3 Quest Diagnostics Drug of Abuse (DOA) Testing Product Introduction
  • 7.7.4 Quest Diagnostics Response to COVID-19 and Related Developments
• 7.8 Express Diagnostics Int'l
  • 7.8.1 Express Diagnostics Int'l Business Overview
  • 7.8.2 Express Diagnostics Int'l Drug of Abuse (DOA) Testing Quarterly Revenue, 2020
  • 7.8.3 Express Diagnostics Int'l Drug of Abuse (DOA) Testing Product Introduction
  • 7.8.4 Express Diagnostics Int'l Response to COVID-19 and Related Developments
• 7.9 Psychemedics
  • 7.9.1 Psychemedics Business Overview
  • 7.9.2 Psychemedics Drug of Abuse (DOA) Testing Quarterly Revenue, 2020
  • 7.9.3 Psychemedics Drug of Abuse (DOA) Testing Product Introduction
  • 7.9.4 Psychemedics Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US